A retrospective study of 40 Chinese patients found that extramedullary relapse after BCMA-directed CAR-T therapy is linked to significantly worse survival and poorer responses to subsequent salvage treatment. The findings highlight extramedullary disease as a key clinical determinant of CAR-T durability rather than a uniform outcome pattern. The report frames the clinical problem as patients who relapse outside the bone marrow compartment, where tumor biology and therapeutic access differ from typical marrow involvement. For the small cohort, the association remained notable enough to affect expectations for sequencing and follow-up management. In practical terms, the study supports closer monitoring and risk stratification for extramedullary progression after CAR-T. It also informs how teams might design post-CAR-T interventions or trials aimed at preventing sanctuary-site escape. As CAR-T moves toward broader earlier-line use, these real-world outcome signals can influence patient selection criteria and trial endpoints focused on durable remission.